Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2786

Sigma-Aldrich

WRG-28

≥98% (HPLC)

Synonym(s):

DDR2 inhibitor WRG-28, N-Ethyl-4-[[(3-oxo-3H-phenoxazin-7-yl)oxy]methyl]-benzenesulfonamide

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
€70.60
25 MG
€285.00

€70.60

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
€70.60
25 MG
€285.00

About This Item

Empirical Formula (Hill Notation):
C21H18N2O5S
CAS Number:
1913291-02-7
Molecular Weight:
410.44
MDL number:
MFCD32201040
UNSPSC Code:
12352200
NACRES:
NA.77

€70.60

Please contact Customer Service for Availability
Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to very dark orange

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[S](=O)(=O)(NCC)c1ccc(cc1)COc2cc3[o]c4c(nc3cc2)cc[c](c4)=O

InChI key

AARVTLIQNGAELZ-UHFFFAOYSA-N

Biochem/physiol Actions

WRG-28 is a potent, selective and extracellularly acting allosteric inhibitor of discoidin domain receptor 2 (DDR2) that potently inhibits invasion and migration in mice model of breast cancer. WRG-28 inhibits metastatic breast tumor cell colonization in the lungs.
potent, selective and extracellularly acting allosteric inhibitor of DDR2 that potently inhibits invasion and migration tumor cells

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000120695
0000120694
0000112363

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pengwei Lu et al.
Artificial cells, nanomedicine, and biotechnology, 47(1), 3955-3960 (2019-10-02)
Belinostat is a histone deacetylase inhibitor drug capable of regulating cell growth in diverse cancers. Nonetheless, little information clarified the role of Belinostat in breast cancer. Hence, the functions of Belinostat in breast cancer cells survival was disclosed in this
Saumya S Gurbani et al.
Tomography (Ann Arbor, Mich.), 5(1), 53-60 (2019-03-12)
Histone deacetylases regulate a wide variety of cellular functions and have been implicated in redifferentiation of various tumors. Histone deacetylase inhibitors (HDACi) are potential pharmacologic agents to improve outcomes for patients with gliomas. We assessed the therapeutic efficacy of belinostat
Frank C Passero et al.
British journal of haematology, 188(2), 295-308 (2019-08-28)
Ixazomib activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. In this present study, we determined the mechanistic basis for ixazomib combination with the HDAC
Xiaoyan Qiu et al.
Cellular reprogramming, 22(1), 14-21 (2020-02-06)
To improve the isolation efficiency of parthenogenetic embryonic stem cells (pESCs) in mice, it is necessary to optimize the method to increase in vitro developmental competence of mice parthenogenetic blastocysts. Therefore, this study aims to investigate an optimal method for
Francesco Marampon et al.
Cancer letters, 461, 90-101 (2019-07-22)
This study describes the in vitro and in vivo activity of PXD-101 (Belinostat), a novel hydroxamic acid-type pan-HDACs inhibitor characterized by a larger safety and efficacy, on myogenic-derived PAX3/FOXO1 fusion protein positive (RH30) or negative (RD) expressing rhabdomyosarcoma (RMS) cell
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service